Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 9/20 | 0.56 |
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.54 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24575084 | 1.00 | IL1B (0.56) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL28934266 | 1.00 | IL1B (0.56) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL29275600 | 0.99 | IL1B (0.55) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL29276117 | 0.99 | IL1B (0.55) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL30214109 | 0.99 | IL1B (0.55) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL31057311 | 0.98 | NLRP3 (0.57) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL24575646 | 0.90 | NLRP3 (0.59) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL24575648 | 0.90 | NLRP3 (0.59) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL24575703 | 0.89 | NLRP3 (0.68) | IL1BNLRP3CHEK2CHEK1KCNH2 | |
| SCHEMBL31057145 | 0.89 | NLRP3 (0.68) | IL1BNLRP3CHEK2CHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | claimed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118234711-A | Cyclopyridazine compounds | 尼科治疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4375274-A1 | ANNULATED PYRIDAZINE COMPOUND | Nico Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-116969920-A | Fused pyridazine derivative, preparation method and medical application thereof | 上海辉启生物医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023003002-A1 | ANNULATED PYRIDAZINE COMPOUND | アステラス製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | IL1B 10/4885NLRP3 1/4885CHEK2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.